Published in Cerebellum on August 01, 2013
Continuous theta-burst stimulation modulates tactile synchronization. BMC Neurosci (2013) 0.79
Impaired temporal processing of tactile and proprioceptive stimuli in cerebellar degeneration. PLoS One (2013) 0.78
Tactile and proprioceptive temporal discrimination are impaired in functional tremor. PLoS One (2014) 0.78
Temporal discrimination threshold with healthy aging. Neurobiol Aging (2016) 0.77
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol (2011) 2.44
Predictors of recovery of responsiveness in prolonged anoxic vegetative state. Neurology (2013) 2.26
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol (2013) 2.24
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet (2007) 2.17
Pelizaeus-Merzbacher-Like disease presentation of MCT8 mutated male subjects. Ann Neurol (2009) 2.12
Sensorimotor integration in movement disorders. Mov Disord (2003) 2.09
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol (2008) 1.96
Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol (2012) 1.95
Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am J Hum Genet (2012) 1.88
Consensus: Motor cortex plasticity protocols. Brain Stimul (2008) 1.86
Do primary adult-onset focal dystonias share aetiological factors? Brain (2007) 1.83
Epidemiology of primary dystonia. Lancet Neurol (2004) 1.71
PARK6-linked parkinsonism occurs in several European families. Ann Neurol (2002) 1.68
Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain (2003) 1.68
Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord (2010) 1.66
A comparative study of primary and secondary hemifacial spasm. Arch Neurol (2006) 1.65
The focal dystonias: current views and challenges for future research. Mov Disord (2013) 1.62
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord (2013) 1.62
Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage. J Cell Biol (2007) 1.59
Ross syndrome: a rare or a misknown disorder of thermoregulation? A skin innervation study on 12 subjects. Brain (2006) 1.55
Cholestenoic acids regulate motor neuron survival via liver X receptors. J Clin Invest (2014) 1.55
Quantification of myelinated endings and mechanoreceptors in human digital skin. Ann Neurol (2003) 1.44
How much phenotypic variation can be attributed to parkin genotype? Ann Neurol (2003) 1.44
Case of acute motor conduction block neuropathy (AMCBN). Muscle Nerve (2009) 1.43
Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain (2008) 1.43
Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain (2006) 1.41
Study of multimodal evoked potentials in patients with type 1 Gaucher's disease. J Child Neurol (2005) 1.40
Variable phenotype in a P102L Gerstmann-Sträussler-Scheinker Italian family. Can J Neurol Sci (2003) 1.40
Myelinated nerve endings in human skin. Muscle Nerve (2007) 1.30
Mitochondrial respiratory dysfunction in familiar parkinsonism associated with PINK1 mutation. Neurochem Res (2008) 1.26
Skin sympathetic adrenergic innervation: an immunofluorescence confocal study. Ann Neurol (2006) 1.26
Slow repetitive TMS for drug-resistant epilepsy: clinical and EEG findings of a placebo-controlled trial. Epilepsia (2007) 1.22
Pathophysiology of somatosensory abnormalities in Parkinson disease. Nat Rev Neurol (2013) 1.17
Correlation between cortical plasticity, motor learning and BDNF genotype in healthy subjects. Exp Brain Res (2011) 1.16
Depression comorbidity in spinocerebellar ataxia. Mov Disord (2011) 1.15
A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score. Muscle Nerve (2010) 1.15
Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord (2008) 1.14
The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J Neuroimmunol (2005) 1.13
The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. PLoS One (2013) 1.09
Facioscapulohumeral muscular dystrophy: new insights from compound heterozygotes and implication for prenatal genetic counselling. J Med Genet (2012) 1.07
Screening of ARHSP-TCC patients expands the spectrum of SPG11 mutations and includes a large scale gene deletion. Hum Mutat (2009) 1.07
Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics (2010) 1.06
Validity of family history data on primary adult-onset dystonia. Arch Neurol (2004) 1.05
Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy. Brain (2013) 1.05
Phasic voluntary movements reverse the aftereffects of subsequent theta-burst stimulation in humans. J Neurophysiol (2008) 1.03
Assessing the role of DRD5 and DYT1 in two different case-control series with primary blepharospasm. Mov Disord (2007) 1.03
Temporal discrimination in patients with dystonia and tremor and patients with essential tremor. Neurology (2012) 1.02
PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. Mov Disord (2006) 1.02
Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum (2008) 1.01
Attention influences the excitability of cortical motor areas in healthy humans. Exp Brain Res (2007) 1.01
Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. Arch Neurol (2004) 1.01
Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol (2002) 1.01
Autosomal dominant hereditary spastic paraplegia: DHPLC-based mutation analysis of SPG4 reveals eleven novel mutations. Hum Mutat (2005) 1.01
Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry (2012) 1.00
Spastic paraplegia with thin corpus callosum: description of 20 new families, refinement of the SPG11 locus, candidate gene analysis and evidence of genetic heterogeneity. Neurogenetics (2006) 1.00
Mirror movements in patients with Parkinson's disease. Mov Disord (2008) 1.00
Relationship between eye symptoms and blepharospasm: a multicenter case-control study. Mov Disord (2005) 1.00
Brain white matter damage in SCA1 and SCA2. An in vivo study using voxel-based morphometry, histogram analysis of mean diffusivity and tract-based spatial statistics. Neuroimage (2008) 1.00
Tremor in primary adult-onset dystonia: prevalence and associated clinical features. J Neurol Neurosurg Psychiatry (2012) 0.99
DNA damage induced by polyglutamine-expanded proteins. Hum Mol Genet (2003) 0.99
A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. Pharmacol Res (2006) 0.99
Impairment of individual finger movements in Parkinson's disease. Mov Disord (2003) 0.99
Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol (2012) 0.99
Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. Neurol Sci (2009) 0.98
Voluntary, spontaneous, and reflex blinking in Parkinson's disease. Mov Disord (2008) 0.98
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J Neurol (2012) 0.98
Central effects of botulinum toxin type A: evidence and supposition. Mov Disord (2004) 0.97
A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS One (2011) 0.97
Electrophysiological characterisation in hereditary spastic paraplegia type 5. Clin Neurophysiol (2010) 0.96
The neurobiology of falls. Neurol Sci (2012) 0.96
Facial bradykinesia. J Neurol Neurosurg Psychiatry (2012) 0.96
Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. Am J Gastroenterol (2005) 0.96
Repetitive magnetic stimulation of cortical motor areas in Parkinson's disease: implications for the pathophysiology of cortical function. Mov Disord (2002) 0.96
Cutaneous innervation of the human face as assessed by skin biopsy. J Anat (2012) 0.96
Novel Italian family supports clinical and genetic heterogeneity of primary adult-onset torsion dystonia. Mov Disord (2002) 0.96
Centronuclear myopathy related to dynamin 2 mutations: clinical, morphological, muscle imaging and genetic features of an Italian cohort. Neuromuscul Disord (2013) 0.95